Major Estimate Revision • May 19
Consensus revenue estimates decrease by 20% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$2.81m to US$2.24m. EPS estimate unchanged from -US$1.61 per share at last update. Pharmaceuticals industry in the US expected to see average net income decline 12% next year. Consensus price target of US$10.00 unchanged from last update. Share price fell 8.1% to US$1.59 over the past week. Reported Earnings • May 14
First quarter 2026 earnings: EPS and revenues miss analyst expectations First quarter 2026 results: US$0.39 loss per share. Revenue: US$493.0k (up 1.6% from 1Q 2025). Net loss: US$2.06m (loss widened 24% from 1Q 2025). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 18%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • May 08
SenesTech, Inc. to Report Q1, 2026 Results on May 12, 2026 SenesTech, Inc. announced that they will report Q1, 2026 results After-Market on May 12, 2026 Tillkännagivande • May 01
SenesTech, Inc., Annual General Meeting, Jun 09, 2026 SenesTech, Inc., Annual General Meeting, Jun 09, 2026. Location: 13430 north dysart road, suite 105, surprise, arizona 85379., United States New Risk • Mar 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.86m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (204% increase in shares outstanding). Market cap is less than US$10m (US$9.86m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$2.9m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.2m revenue). Reported Earnings • Mar 15
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: US$1.95 loss per share. Revenue: US$2.22m (up 20% from FY 2024). Net loss: US$6.38m (loss widened 3.2% from FY 2024). Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 29%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Mar 10
SenesTech, Inc. to Report Q4, 2025 Results on Mar 12, 2026 SenesTech, Inc. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026 New Risk • Feb 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (405% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.2m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.3m revenue). Market cap is less than US$100m (US$10.4m market cap). Tillkännagivande • Feb 03
Senestech's Evolve Approves in New Zealand SenesTech, Inc. has announced that its product, Evolve, has been approved for use in New Zealand by the Ministry for Primary Industries. Evolve is a fertility control solution designed to manage rodent populations by restricting reproduction, offering a non-lethal and environmentally responsible alternative to traditional rodenticides. This approval aligns with New Zealand's Predator Free 2050 initiative, which aims to eradicate invasive predators to protect native species. The initiative is a significant conservation effort, with New Zealand planning to invest over $4.5 billion. SenesTech's exclusive distribution partner, Evicom, has already received its initial stocking order, and regular shipments are expected to follow. This approval supports SenesTech's strategy to become a global leader in sustainable fertility control solutions and aligns with changing regulatory standards and environmental policies. New Risk • Jan 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.92m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (405% increase in shares outstanding). Market cap is less than US$10m (US$9.92m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.2m net loss in 3 years). Revenue is less than US$5m (US$2.3m revenue). New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (405% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.2m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.3m revenue). Market cap is less than US$100m (US$15.0m market cap). Reported Earnings • Nov 12
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: US$0.28 loss per share (improved from US$2.07 loss in 3Q 2024). Revenue: US$690.0k (up 43% from 3Q 2024). Net loss: US$1.30m (loss narrowed 14% from 3Q 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) exceeded analyst estimates by 20%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Nov 04
SenesTech, Inc. to Report Q3, 2025 Results on Nov 10, 2025 SenesTech, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 10, 2025 Reported Earnings • Aug 10
Second quarter 2025 earnings released: US$0.87 loss per share (vs US$3.08 loss in 2Q 2024) Second quarter 2025 results: US$0.87 loss per share. Revenue: US$625.0k (up 36% from 2Q 2024). Net loss: US$1.62m (loss widened 2.0% from 2Q 2024). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Aug 01
SenesTech, Inc. to Report Q2, 2025 Results on Aug 07, 2025 SenesTech, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Tillkännagivande • Jul 11
SenesTech, Inc. Appoints Lynn Y. Graham as Independent Director and Member of the Commercialization Committee SenesTech, Inc. announced that on July 5, 2025, the Board of Directors authorized an increase in the size of the Board to seven members and appointed Lynn Y. Graham to serve on the Board as an independent director. Ms. Graham will serve as a Class III director until the 2028 Annual Meeting of Stockholders or until her earlier death, resignation, or removal or until a successor is elected and qualified. Ms. Graham was also appointed to serve as a member of the Commercialization Committee of the Board. New Risk • Jun 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (251% increase in shares outstanding). Market cap is less than US$10m (US$8.57m market cap). Minor Risk Revenue is less than US$5m (US$1.9m revenue). Tillkännagivande • Jun 26
SenesTech's Evolve Rodent Birth Control Proven in Urban Rodent Hotspots from Hong Kong to San Francisco SenesTech, Inc. announced compelling results from two major urban deployments -- one in Hong Kong and one in San Francisco -- showing how pairing Evolve™? Rat birth Control with traditional poison bait stations delivers faster, more sustainable rodent control where it's needed most. Urban centers worldwide face constant rodent challenges due to dense infrastructure, hard-to-access breeding sites, and abundant food sources. Even the most aggressive traditional rodenticide programs often fall short over time, as rodents adapt to poisons and continue to reproduce unchecked. In both Hong Kong and San Francisco, pest management teams implemented a novel integrated strategy: deploying Evolve's palatable soft bait alongside conventional rodenticide blocks within standard bait stations across infested buildings and surrounding areas. This hybrid approach tackles two critical issues simultaneously: Immediate population knockdown via targeted poison baiting; Long-term population suppression by disrupting rodent reproduction cycles with fertility control. In Hong Kong, this method was applied in a high-density mixed-use building with persistent rodent activity. Fertility control solutions like Evolve align with changing environmental regulations and public demand for humane, low-toxicity pest management. For pest control professionals and property owners, this means improved outcomes, new service offerings, and better ROI from each deployment. For investors, it signals a rapidly growing global market for next-generation rodent control solutions that complement and enhance traditional tools. Tillkännagivande • Jun 25
SenesTech, Inc. and Irvine Campus Housing Authority Conclude Successful Field Trial of Evolve Rat Birth Control at UC Irvine SenesTech, Inc. announced the successful conclusion of a nine-month field trial of Evolve Rat birth Control at the University Hills (UHills) residential community at the University of California, Irvine. The project was conducted in partnership with the Irvine Campus Housing Authority (ICHA) and reflects a growing commitment to ecologically responsible pest management. The initiative began in September 2024 and marked the exclusive use of Evolve Rat birth Control across common areas of the UHills community. This deployment was part of a broader effort driven by resident pressure on ICHA to transition away from rodenticides in favor of integrated pest management (IPM) strategies that prioritize environmental safety and wildlife preservation. Located adjacent to a wildlife reserve, the community's shift away from rodenticides further supports the protection of local wildlife and ecosystems. Evolve was deployed across 267 bait stations previously containing rodenticides and snap traps. According to field observations, rats consumed 98% of Evolve across all stations each month, indicating high acceptance and performance of the bait. As expected, consumption dropped as the rat population dropped. The field trial also supported the efforts of the HOOT Group (Help Our Owls Thrive), a grassroots initiative formed by UHills residents to promote owl nesting and reduce rodenticide use. Together, the partners implemented a range of actions, including installation of enclosed snap traps, removal of rodent harborage areas, and installation of barn owl nesting boxes to encourage natural predation. As a result of the collaboration, rodenticides have been eliminated from all 267 bait stations across common areas in UHills. SenesTech is pleased to have contributed to this transition and to support communities like UHills and organizations like ICHA and HOOT that are leading the way in redefining effective, responsible rodent control. A multi-pallet restocking order for continued deployment and expansion is being placed currently. Tillkännagivande • Jun 13
Senestech, Inc. Expands Use of Evolve Rodent Birth Control Following Successful Pilot SenesTech, Inc. announced that the City of Baltimore has concluded its initial pilot program and is now transitioning to a broader deployment of Evolve™?, one of the Company's non-lethal rodent birth control products. Following the limited, controlled deployment earlier this year, Baltimore officials have determined that Evolve align with the city's integrated pest management (IPM) goals, offering a sustainable method for addressing persistent rodent population challenges. The expanded deployment will focus on areas that experienced measurable improvements during the pilot phase, with additional sites to be added in coordination with local pest management teams. Evolve works by targeting the root cause of rodent infestations--reproduction. Designed to be used alongside traditional pest control methods, Evolve is a palatable soft bait that limits fertility in both male and female rats. Classified as a minimum-risk pesticide by the EPA, it poses no known risk to people, pets, or the environment when used as directed. The City's decision to proceed with broader implementation follows several months of evaluation, during which Evolve was deployed in key locations as part of an integrated effort to reduce rodent activity. Baltimore's pest control personnel reported enhanced results when Evolve was included in their existing protocols. SenesTech will continue to support the City of Baltimore throughout the rollout, including providing training, deployment guidance, and ongoing technical assistance. Reported Earnings • May 09
First quarter 2025 earnings released: US$1.28 loss per share (vs US$3.56 loss in 1Q 2024) First quarter 2025 results: US$1.28 loss per share (improved from US$3.56 loss in 1Q 2024). Revenue: US$485.0k (up 17% from 1Q 2024). Net loss: US$1.67m (loss narrowed 9.1% from 1Q 2024). Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • May 02
SenesTech, Inc. to Report Q1, 2025 Results on May 08, 2025 SenesTech, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 New Risk • Apr 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (240% increase in shares outstanding). Market cap is less than US$10m (US$3.16m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$5.1m net loss in 3 years). Revenue is less than US$5m (US$1.9m revenue). Tillkännagivande • Apr 22
SenesTech, Inc., Annual General Meeting, Jun 09, 2025 SenesTech, Inc., Annual General Meeting, Jun 09, 2025. Location: 13430 north dysart road, suite 105, surprise, arizona 85379., United States Reported Earnings • Mar 13
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: US$8.86 loss per share (improved from US$115 loss in FY 2023). Revenue: US$1.86m (up 56% from FY 2023). Net loss: US$6.18m (loss narrowed 20% from FY 2023). Revenue missed analyst estimates by 10.0%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in the US. New Risk • Mar 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Market cap is less than US$10m (US$3.11m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$5.3m net loss in 3 years). Revenue is less than US$5m (US$1.7m revenue). Tillkännagivande • Mar 07
SenesTech, Inc. to Report Q4, 2024 Results on Mar 12, 2025 SenesTech, Inc. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025 Tillkännagivande • Feb 11
SenesTech Expands E-Commerce Presence with Evolve Rodent Birth Control™? Now Available on Tractor Supply.com SenesTech, Inc. announced that its Evolve™? Rodent birth Control product line is now available for purchase on TractorSupply.com. This expansion represents another key milestone in SenesTech's e-commerce growth strategy, bringing its innovative and effective rodent control solution to a broader customer base nationwide. Tractor Supply Company is the larger rural lifestyle retailer in the United States, operating over 2,200 stores across 49 states. Tractor Supply serves farmers, ranchers, homeowners, and outdoor enthusiasts with a wide range of products, including pet and livestock supplies, hardware, and pest control solutions. Tractor Supply's e-commerce platform has seen significant growth, complementing its brick-and-mortar presence and providing customers with convenient access to quality products online. The availability of Evolve Rodent birth Control on TractorSupp Supply.com adds to SenesTech's growing online retail footprint, which already includes Amazon, Walmart.com, and DIYpestcontrol.com. This multi-platform approach aligns with the SenesTech's strategy to expand its e-commerce presence and make Evolve more accessible to consumers and businesses seeking a humane and effective solution for rodent control. Tillkännagivande • Jan 11
Joshua M. Moss to Join the Board of Directors of SenesTech, Inc SenesTech, Inc. announced that Joshua M. Moss will be joining the Board of Directors of the company. Joshua M. Moss is the co-founder, Managing Director, and Portfolio Manager at EAM Global Investors, a boutique investment firm specializing in non-U.S. and emerging market equities with approximately $3 billion in assets under management. With over 20 years of experience in institutional investment management, Josh has a proven track record of success in portfolio management, team leadership, and global business development. He began his career at Credit Suisse, focusing on investment banking and equity research, and later held senior roles at Allianz Global Investors, where he managed significant portfolios and led sector teams. At EAM, he has overseen the firm's growth from its inception, successfully launching and managing strategies such as International Small Cap and Emerging Markets Small Cap. Josh holds an MBA in Finance from the UCLA Anderson School of Management and a BA in History from the University of California, San Diego. Based in the San Diego area, he is fluent in Spanish and leverages his deep expertise to deliver consistent alpha generation while fostering sustainable, long-term investment strategies. Reported Earnings • Nov 14
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: US$2.07 loss per share (improved from US$55.94 loss in 3Q 2023). Revenue: US$482.0k (up 34% from 3Q 2023). Net loss: US$1.51m (loss narrowed 22% from 3Q 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Nov 13
SenesTech Launches Evolve Rodent Birth Control on Walmart Marketplace SenesTech, Inc. announced a significant expansion in the distribution of its rodent birth control product. Evolve Rat and Evolve Mouse are now available on Walmart Marketplace, one of the largest and most trusted eCommerce platforms in the world. SenesTech developed its proprietary technology for managing rat and mouse populations--through fertility control. Evolve is the Company's minimum-risk soft bait, providing a proactive approach to rodent control without the use of traditional poisons. When used as directed, Evolve is safe for people, pets, wildlife and the environment because it's not a poison. Evolve Rat and Evolve Mouse target the root cause of rodent overpopulation by controlling the fertility in both male and female rodents. Instead of simply reacting to rodent infestations with poisons, the active ingredient in Evolve has been shown to effectively lower fertility rates which significantly reduces populations. Plus, it's highly palatable, easy to use, and versatile for use in various environments, inside and out. Furthermore, as regulations in states like California increasingly restrict the use of traditional poisons, consumers and professionals alike are turning to innovative, non-poisonous solutions such as Evolve. Tillkännagivande • Nov 06
SenesTech, Inc. to Report Q3, 2024 Results on Nov 12, 2024 SenesTech, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 Tillkännagivande • Oct 31
SenesTech, Inc.'s Evolve™ Registers in Hong Kong; Offering a Revolutionary Non-Lethal Rodent Control Solution SenesTech, Inc. announced the successful registration of Evolve™ in Hong Kong. Hong Kong welcomes Evolve™, an innovative, non-lethal rodent birth control solution designed to target rat infestations at their root. Unlike conventional methods, Evolve restricts rodent reproduction, offering an effective and humane way to manage infestations without posing risks to humans, pets, wildlife, or the environment. As a sustainable alternative to toxic baits and inhumane traps, Evolve represents a breakthrough in tackling Hong Kong's escalating rat problem. Developed by U.S.-based SenesTech, a leader in the animal pest fertility control industry, Evolve is the first and only soft bait specifically designed to reduce rat populations by limiting fertility. Launched earlier this year, Evolve offers a non-lethal, eco-friendly solution that has earned the "minimum risk" designation from the U.S. Environmental Protection Agency (EPA). This classification (FIFRA 25(b) exempt) highlights its low-risk profile for humans, the environment, and non-target species. Building on the success of Evolve Rat, SenesTech expanded its product line in May with the introduction of Evolve™ Mouse. Both products integrate seamlessly into existing pest management programs, providing long-term, sustainable control of rodent populations. In Hong Kong, Evolve is exclusively distributed by Fruit Tree Limited and its subsidiaries, Nobedbugs-HK and Chinchex Limited, prominent pest control service providers that have worked extensively with the Food and Environmental Hygiene Department (FEHD) of the HKSAR government to register the products. Alvarino noted the shortcomings of conventional methods, such as poisonous baits and traps, which may quickly eliminate rodents but fail to address the long-term growth of rodent populations. With an estimated rat population of 2.5 million, Hong Kong faces a serious rodent problem. Despite recent efforts by the FEHD, which reported the capture of 65,500 live rodents last year—a 39% increase from the previous year—the infestation continues to expand. Targeting the B2B market, Fruit Tree Limited sees vast potential for Evolve in Hong Kong, with plans to expand into Mainland China. Initially, Evolve™ Rat and Evolve™ Mouse will be available in 1.5 lb, 3 lb and 6 lb packages through NoBedBugs-HK. Reported Earnings • Aug 09
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2024 results: US$3.08 loss per share (improved from US$83.60 loss in 2Q 2023). Revenue: US$459.0k (up 51% from 2Q 2023). Net loss: US$1.58m (loss narrowed 21% from 2Q 2023). Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Aug 06
SenesTech Receives Notification from Nasdaq Due to Non-Compliance with Nasdaq’s Audit Committee Requirements as Set Forth in Nasdaq Listing Rule 5605 SenesTech, Inc. announced that Delphine François Chiavarini’s position as a member of the company’s board of directors (the ‘Board’) expired at its 2024 annual meeting of stockholders. Ms. François Chiavarini also served as a member of the company’s audit committee (the ‘Audit Committee’). On July 31, 2024, the company received a letter from the listing qualifications staff (the ‘Staff’) of The Nasdaq Stock Market (‘Nasdaq’) providing notification that due to the departure of Ms. François Chiavarini from the company’s Board and Audit Committee effective July 11, 2024, the company no longer comply with Nasdaq’s audit committee requirements as set forth in Nasdaq Listing Rule 5605 (the ‘Rule’). The Rule requires, among other things, that the Audit Committee be comprised of at least three independent directors. In accordance with Nasdaq Listing Rule 5605(c)(4), Nasdaq will provide the company a cure period in order to regain compliance as follows (i) until the earlier of the company’s next annual stockholders’ meeting or July 11, 2025; or (ii) if the next annual stockholders’ meeting is held before January 7, 2025, then the company must evidence compliance no later than January 7, 2025. In the event the company do not regain compliance prior to the expiration of the applicable cure period, the Nasdaq Listing Rules require the Staff to provide written notification to the company that its securities will be delisted. At that time, the company may appeal the Staff’s determination to a Nasdaq hearings panel. The Nasdaq notification has no immediate effect on the listing of the company’s common stock on the Nasdaq Capital Market. The company intend to rely on the cure period to re-establish compliance with the Rule. The company is in the process of identifying and selecting a Board member who qualifies as independent and meets the audit committee criteria set forth in the Rule prior to the expiration of the cure period. However, there can be no assurance that the company will regain compliance with the Rule or maintain compliance with other Nasdaq continued listing requirements. Tillkännagivande • Aug 02
SenesTech, Inc. to Report Q2, 2024 Results on Aug 08, 2024 SenesTech, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2024 New Risk • Jul 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (over 19x increase in shares outstanding). Market cap is less than US$10m (US$2.48m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$5.8m net loss in 3 years). Revenue is less than US$5m (US$1.4m revenue). Tillkännagivande • Jun 21
SenesTech, Inc. has filed a Follow-on Equity Offering in the amount of $1.575944 million. SenesTech, Inc. has filed a Follow-on Equity Offering in the amount of $1.575944 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Tillkännagivande • May 17
SenesTech, Inc., Annual General Meeting, Jul 11, 2024 SenesTech, Inc., Annual General Meeting, Jul 11, 2024. Location: 23460 n. 19th ave., suite 110, arizona 85027., phoenix United States Major Estimate Revision • May 16
Consensus EPS estimates fall by 67% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.66 to -US$1.10 per share. Revenue forecast unchanged at US$2.24m. Pharmaceuticals industry in the US expected to see average net income growth of 3.3% next year. Consensus price target of US$3.50 unchanged from last update. Share price fell 26% to US$0.68 over the past week. Reported Earnings • May 13
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: US$0.36 loss per share (improved from US$15.89 loss in 1Q 2023). Revenue: US$415.0k (up 78% from 1Q 2023). Net loss: US$1.83m (loss narrowed 10% from 1Q 2023). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 5.9%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Feb 28
Nasdaq Determines SenesTech Eligible for an Additional 180 Calendar Day Period, or Until August 19, 2024, to Regain Compliance with the Minimum Bid Price Requirement On February 26, 2024, SenesTech, Inc. received notice from the listing qualifications staff (the ‘Staff’) of The Nasdaq Stock Market (‘Nasdaq’) indicating that, while the company has not regained compliance with the Rule, the Staff has determined that the company is eligible for an additional 180 calendar day period, or until August 19, 2024, to regain compliance. The Staff’s determination was based on (i) the company’s meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and (ii) the company’s providing written notice to Nasdaq of the company’s intent to cure the deficiency during this second compliance period by effecting a reverse stock split, if necessary. If at any time during this second 180-day period the closing bid price of the company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide written confirmation of compliance. If compliance cannot be demonstrated by August 19, 2024, the Staff will provide written notification to the company that its common stock will be delisted. At that time, the company may appeal the Staff’s determination to a Nasdaq hearings panel. There can be no assurance that the company will regain compliance with the Rule or maintain compliance with other Nasdaq continued listing requirements. As previously disclosed, on August 25, 2023, the company received a letter from Nasdaq providing notification that the bid price for the company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days and the company’s common stock no longer met the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2) (the ‘Rule’). The company were provided a period of 180 calendar days, or until February 21, 2024, in which to regain compliance with the Rule. Major Estimate Revision • Feb 28
Consensus EPS estimates upgraded to US$0.66 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.83 to -US$0.66 per share. Revenue forecast unchanged from US$2.25m at last update. Pharmaceuticals industry in the US expected to see average net income decline 0.5% next year. Consensus price target of US$3.50 unchanged from last update. Share price fell 20% to US$0.93 over the past week. New Risk • Feb 22
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Shareholders have been substantially diluted in the past year (over 83x increase in shares outstanding). Market cap is less than US$10m (US$5.51m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$5.9m net loss in 3 years). Revenue is less than US$5m (US$1.2m revenue). Tillkännagivande • Feb 16
SenesTech, Inc. to Report Q4, 2023 Results on Feb 21, 2024 SenesTech, Inc. announced that they will report Q4, 2023 results at 5:00 PM, US Eastern Standard Time on Feb 21, 2024 Tillkännagivande • Jan 08
SenesTech Partners with Global Leader in Irrigation Solutions to Expand Evolve Soft Bait to Open Field Agriculture Applications SenesTech, Inc. announced the expansion of EvolveTM, its innovative soft bait fertility control solution, into the broader market of open field agriculture. This expansion partners with a global leader in irrigation solutions for sustainable agriculture, and will begin at a California dairy and almond grower. Evolve addresses the fundamental issue of rodent overpopulation by focusing on the rapid reproduction of rats. Evolve controls the population by reducing or eliminating the fertility of rats, rather than trying to keep up with the growing numbers of an infestation with poisons alone. The active ingredient in Evolve effectively reduces fertility in rats in numerous independent studies. Evolve is highly palatable to rats, easy to deploy, offers diverse placement in many different environments and is priced competitively to rodenticide alternatives. The broader agricultural market represents a significant opportunity for Evolve. Rodents are reportedly responsible for destroying nearly 20% of the world's stored food supply due to consumption and contamination. Further, California has enacted legislation restricting the use of the four major second generation anticoagulant rodenticides (SGARs), or poisons, which has created a need in the market for non-lethal, effective pest control alternatives. Tillkännagivande • Dec 05
SenesTech's ContraPest Registered for Use in Puerto Rico to Combat Rat Infestations SenesTech, Inc. announced its ContraPest® products have been registered for sale and immediate use in Puerto Rico. ContraPest is the first and only EPA-registered rat contraceptive impacting both male and female rats and fits seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. The Company is also in the process of completing Puerto Rico product registration for Evolve™, SenesTech's all new, soft bait product that has similar efficacy to ContraPest but in a user friendly non-liquid format. SenesTech currently offers four unique fertility control options to manage rat infestations, including the following: The Ultimate Bait System™ with ContraPest® is designed for pest management professionals with its larger size and standard bait box deployment. The Isolate Bait System™ with ContraPest® is a more efficient and easier-to-use bait system utilizing an integrated tank-tray unit catering to both professionals and the do-it-yourself market. The Elevate Bait SystemTM with ContraPest® was uniquely designed to be easily deployed above ground with multiple options for mounting in the rafters of barns, granaries, storage and manufacturing facilities – wherever rats are feeding, transiting or hiding. The novel suspended bait station is easily accessible by rats, but out of the way of people, pets, livestock, food stores, etc. EvolveTM Soft Bait, the first and only soft bait contraceptive for rats in a highly palatable, user-friendly format, and convenient for professionals and consumers alike to deploy. New Risk • Nov 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.9m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (over 13x increase in shares outstanding). Market cap is less than US$10m (US$1.53m market cap). Minor Risk Revenue is less than US$5m (US$1.2m revenue). Tillkännagivande • Nov 23
SenesTech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market On November 20, 2023, SenesTech, Inc. received a letter from the listing qualifications staff of The Nasdaq Stock Market providing notification that we no longer meet the minimum 500,000 publicly held shares requirement pursuant to Nasdaq Listing Rule 5550(a)(4). As a result of our previously announced 1-for-12 reverse stock split of our common stock, the aggregate number of our outstanding shares of common stock was reduced from 5,899,060 shares on a pre-reverse-split basis to a total of 492,293 shares outstanding on a post-reverse split basis. In accordance with Nasdaq rules, we have until January 4, 2024 to provide the Staff with a specific plan to achieve and sustain compliance with all listing requirements of The Nasdaq Capital Market, including the time frame for completion of this plan. After reviewing our plan, Nasdaq will provide written notice of their decision. If Nasdaq does not accept our plan, we will have the opportunity to appeal their decision to a hearings panel. The Nasdaq notification has no immediate effect on the listing of our common stock on The Nasdaq Capital Market. We intend to consider options available to us to achieve compliance with the Nasdaq listing rules and provide our plan to Nasdaq by January 4, 2024. There can be no assurance that we will be able to achieve and sustain compliance with the publicly held shares requirement or will otherwise be in compliance with the other listing standards for The Nasdaq Capital Market. Reported Earnings • Nov 11
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2023 results: US$0.47 loss per share (improved from US$4.33 loss in 3Q 2022). Revenue: US$360.0k (up 44% from 3Q 2022). Net loss: US$1.95m (loss narrowed 26% from 3Q 2022). Revenue missed analyst estimates by 37%. Earnings per share (EPS) exceeded analyst estimates by 45%. Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Nov 03
SenesTech, Inc. to Report Q3, 2023 Results on Nov 09, 2023 SenesTech, Inc. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023 Tillkännagivande • Nov 02
SenesTech Taking Orders for Evolve™ Soft Bait for Rodent Fertility Control SenesTech, Inc. announced the Company is now taking orders from commercial customers for Evolve™ Soft Bait, a solution designed to reduce fertility in rats, for shipment on or before November 13th. The Company already has received advanced purchase commitments from key customers. The minimum-risk solution is the first and only soft bait developed to control pest populations using a breakthrough technology that targets the rat population where it starts, by restricting fertility through nonlethal methods. Evolve targets the root cause of pest problems–rats' ability to rapidly reproduce. The solution controls the population by controlling the fertility of rats, rather than trying to keep up with the growing numbers of an infestation. The active ingredient in Evolve™ effectively reduces fertility in rodents in numerous independent studies. Evolve is highly palatable to rats, easy to deploy, and offers diverse placement in many different environments including municipalities, parks, recreation facilities, sports venues, food processing facilities, correctional facilities, subways, medical facilities, agribusiness, zoos and residential locations. Evolve is priced competitively to rodenticide alternatives. Tillkännagivande • Oct 18
SenesTech, Inc. Launches Evolve Soft Bait for Rodent Fertility Control SenesTech, Inc. announced the launch of EvolveTM Soft Bait ("Evolve"), a solution designed to reduce fertility in rats. The minimum-risk solution is the first and only soft bait developed to control pest populations using a breakthrough technology that targets the rat population where it starts by restricting fertility through nonlethal methods. Targeted to both the professional and consumer markets, Evolve™ Soft Bait is highly palatable to rats, easy to deploy, and offers diverse placement in many different environments including municipalities, parks, recreation facilities, sports venues, food processing facilities, correctional facilities, subways, medical facilities, agribusiness, zoos and residential locations. SenesTech will offer Evolve™ Soft Bait for direct sale to pest management professionals, through distributors, on the Company's e-commerce portal and through big box retailers. Evolve™ Soft Bait targets the root cause of pest problems–rats' ability to rapidly reproduce. The solution controls the population by controlling the fertility of rats, rather than trying to keep up with the growing numbers of an infestation. Evolve™ Soft Bait's key benefits include: Effective fertility control – The active ingredient in Evolve™ Soft Bait is proven to effectively reduce or eliminate fertility in rats, which reduces their population. Long-term solution – Affects the population beginning after one to two breeding cycles (four to six weeks), resulting in reduced pregnancies and less pups born. User-friendly format – The soft bait format is designed to be familiar and convenient for professionals and consumers alike to deploy. Highly palatable – The contraceptive bait is attractive and palatable to rats and lacks negative side effects that cause rats to become bait averse; rats continue to consume it, bringing greater results. Addresses infestation source – Designed to address pest infestations at the source, by reducing the birth rate. Integrates with pest management programs – Works in tandem with traditional rodent control products to provide long-term solutions. Evolve™ Soft Bait joins SenesTech's line of pest control solutions including ContraPest®, a highly palatable liquid rat contraceptive bait. New Risk • Oct 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.2m free cash flow). Shareholders have been substantially diluted in the past year (385% increase in shares outstanding). Market cap is less than US$10m (US$1.32m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$6.7m net loss in 3 years). Share price has been volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$5m (US$1.1m revenue). Tillkännagivande • Aug 29
SenesTech Receives Non-Compliance Letter from Nasdaq On August 25, 2023, SenesTech, Inc. received a letter from the listing qualifications staff (the Staff") of The Nasdaq Stock Market (Nasdaq") providing notification that the bid price for our common stock had closed below $1.00 per share for the previous 30 consecutive business days and our common stock no longer meets the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have an initial period of 180 calendar days, or until February 21, 2024, to regain compliance. To regain compliance, the closing bid price of our common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before February 21, 2024. If we do not regain compliance with Rule 5550(a)(2) by February 21, 2024, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and would need to provide written notice of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq would notify us that our securities would be subject to delisting. In the event of such notification, we may appeal the Staff's determination to delist our securities, but there can be no assurance the Staff would grant our request for continued listing. The Nasdaq notification has no immediate effect on the listing of our common stock on the Nasdaq Capital Market. We intend to actively monitor the bid price of our common stock and our minimum market value of listed securities and will consider options available to us to achieve compliance with the Nasdaq listing rules. There can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market. Reported Earnings • Aug 13
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: US$0.70 loss per share (improved from US$4.21 loss in 2Q 2022). Revenue: US$305.0k (up 10% from 2Q 2022). Net loss: US$1.99m (loss narrowed 22% from 2Q 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 10%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • Aug 04
SenesTech, Inc. to Report Q2, 2023 Results on Aug 10, 2023 SenesTech, Inc. announced that they will report Q2, 2023 results on Aug 10, 2023 Tillkännagivande • Jul 25
SenesTech, Inc. Launches Isolate Bait System for Contrapest SenesTech, Inc. announced the launch of a new delivery system for ContraPest®?, the Isolate Bait System™?. This system also incorporates an enhanced formulation of ContraPest that is expected to provide improved performance of the fertility control bait in the field. The Isolate is paired with a new bait station that is more efficient and economical. Product Overview: The Isolate Bait System is specifically designed based on customer demands for a more efficient and easier-to-use bait system. Quick and Easy Deployment: With a simple peel-off seal, the Is isolate Bait System allows for rapid placement and setup, with users showing up to 80% reduction in time and effort. User-Friendly Design: The integrated tank-tray unit is designed for ease of use, catering to both professionals and the do-it-yourself market. Convenient Size: With a compact 8 fl. oz. size, it is manageable and suitable for all users, enhancing the overall experience, and is recyclable! Increased Efficiency: The new design, along with an enhanced formulation, ensures improved performance in the field, providing superior results. Enhanced Servicing Experience: By combining the tank and tray into one unit, this system simplifies the servicing process, making maintenance quicker and easier. The design combines the tank and tray into one units, and deployment is a simple placement and peel off seal. This simplicity and convenience will expand addressable market to a broader array of customers and accelerate revenue growth as more customers find alternatives that fit their needs better. The ContraPest delivery options now include: Isolate Bait System Ease of use and convenience; Elevate Bait System Targeted for above ground infestations; Ultimate T&T Bait System Larger size for professional use. Reported Earnings • May 13
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: US$0.001 loss per share (improved from US$3.82 loss in 1Q 2022). Revenue: US$233.0k (up 20% from 1Q 2022). Net loss: US$2.04m (loss narrowed 13% from 1Q 2022). Revenue missed analyst estimates by 27%. Earnings per share (EPS) also missed analyst estimates by 63%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Pharmaceuticals industry in the US. Tillkännagivande • May 05
SenesTech, Inc. to Report Q1, 2023 Results on May 11, 2023 SenesTech, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 11, 2023 Breakeven Date Change • Apr 21
No longer forecast to breakeven The analyst covering SenesTech no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$356.0k in 2025. New forecast suggests the company will make a loss of US$8.28m in 2025. Reported Earnings • Mar 18
Full year 2022 earnings released: US$0.016 loss per share (vs US$14.78 loss in FY 2021) Full year 2022 results: US$0.016 loss per share. Revenue: US$1.02m (up 70% from FY 2021). Net loss: US$9.70m (loss widened 17% from FY 2021). Tillkännagivande • Feb 17
Senestech Names Nicole Williams as Chief Revenue Officer SenesTech, Inc. reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal year of record revenue, and will position the Company to further focus on revenue in 2023. The Company has expanded its field sales organization to seven (7), deployed by geography with leadership in both the East and West. Always innovating and improving customer service, the Company is also growing the commercial team by bringing on an E-Commerce Manager to increase product education, awareness, and accessibility to purchase. Price Target Changed • Nov 16
Price target decreased to US$4.00 Down from US$5.00, the current price target is provided by 1 analyst. New target price is 1,952% above last closing price of US$0.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$0.83 next year compared to a net loss per share of US$0.74 last year. Reported Earnings • Aug 12
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: US$0.21 loss per share (down from US$0.14 loss in 2Q 2021). Revenue: US$277.0k (up 73% from 2Q 2021). Net loss: US$2.57m (loss widened 51% from 2Q 2021). Revenue missed analyst estimates by 25%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 328%, compared to a 16% growth forecast for the industry in the US. Reported Earnings • May 13
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: US$0.19 loss per share. Net loss: US$2.33m (loss widened 28% from 1Q 2021). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 9.5%. Over the next year, revenue is forecast to grow 269%, compared to a 7.1% growth forecast for the industry in the US. Price Target Changed • Apr 27
Price target decreased to US$4.00 Down from US$5.00, the current price target is provided by 1 analyst. New target price is 545% above last closing price of US$0.62. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$0.81 next year compared to a net loss per share of US$0.74 last year. Major Estimate Revision • Apr 05
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$1.93m to US$1.61m. EPS estimate increased from -US$0.82 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 3.3% to US$0.74 over the past week. Reported Earnings • Mar 30
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: US$0.74 loss per share (up from US$2.79 loss in FY 2020). Net loss: US$8.27m (loss narrowed 1.3% from FY 2020). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 4.2%. Over the next year, revenue is forecast to grow 222%, compared to a 15% growth forecast for the pharmaceuticals industry in the US. Board Change • Mar 30
High number of new directors Independent Director Jake Leach was the last director to join the board, commencing their role in 2020. Reported Earnings • Nov 13
Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.56 loss in 3Q 2020) Third quarter 2021 results: Net loss: US$2.25m (loss widened 17% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Major Estimate Revision • Aug 20
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$619.0k to US$752.0k. EPS estimate fell from -US$0.67 to -US$0.74 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$4.00 unchanged from last update. Share price rose 8.4% to US$1.67 over the past week. Recent Insider Transactions • Aug 19
Independent Director recently bought US$229k worth of stock On the 18th of August, Jacob Leach bought around 150k shares on-market at roughly US$1.53 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Aug 14
Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.59 loss in 2Q 2020) Second quarter 2021 results: Net loss: US$1.70m (loss widened 4.4% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Reported Earnings • May 17
First quarter 2021 earnings released: US$0.22 loss per share (vs US$1.70 loss in 1Q 2020) First quarter 2021 results: Net loss: US$1.82m (loss narrowed 33% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 17
Forecast to breakeven in 2025 The analyst covering SenesTech expects the company to break even for the first time. New forecast suggests the company will make a profit of US$1.24m in 2025. Average annual earnings growth of 25% is required to achieve expected profit on schedule. Reported Earnings • Mar 27
Full year 2020 earnings released: US$2.64 loss per share (vs US$7.69 loss in FY 2019) Full year 2020 results: Net loss: US$7.94m (loss narrowed 21% from FY 2019). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 18
SenesTech, Inc. to Report Q4, 2020 Results on Mar 25, 2021 SenesTech, Inc. announced that they will report Q4, 2020 results After-Market on Mar 25, 2021 Is New 90 Day High Low • Feb 13
New 90-day high: US$2.28 The company is up 64% from its price of US$1.39 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$0.26 per share. Tillkännagivande • Feb 03
SenesTech, Inc. announced that it has received $10.000004 million in funding On February 2, 2021, SenesTech, Inc. (NasdaqCM:SNES) closed the transaction. The company paid $1,000,000 as issue expenses and received approximately $9,000,000 as net proceeds. Tillkännagivande • Jan 29
SenesTech, Inc. announced that it expects to receive $10.000004 million in funding SenesTech, Inc. (NasdaqCM:SNES) announced that it has entered into securities purchase agreements with institutional and accredited investors for private placement of 4,388,854 common shares at a price of $2.2785 per share for aggregate gross proceeds of up to $10,000,003.839 on January 27, 2021. The company will issue warrants to purchase 2,194,427 shares at an exercise price of $2.216 and are exercisable immediately and have a term of five and one-half years. The transaction is expected to close on or about January 29, 2021, subject to customary closing conditions. Is New 90 Day High Low • Jan 12
New 90-day high: US$1.90 The company is up 1.0% from its price of US$1.88 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Analyst Estimate Surprise Post Earnings • Nov 13
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 54%. Earnings per share (EPS) missed analyst estimates by 95%. Over the next year, revenue is forecast to grow 230%, compared to a 21% growth forecast for the Pharmaceuticals industry in the US. Reported Earnings • Nov 13
Third quarter 2020 earnings released: US$0.56 loss per share Third quarter 2020 results: Net loss: US$1.92m (loss narrowed 26% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. 
